Dr. Michal Bar-Natan, MD
Claim this profileIcahn School of Medicine at Mount Sinai
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
5 reported clinical trials
21 drugs studied
Area of expertise
1Leukemia
BCR-ABL1 positive
CD19 positive
CRLF2 positive
2Lymphoblastic Leukemia-Lymphoma
BCR-ABL1 positive
CD19 positive
CRLF2 positive
Affiliated Hospitals
Clinical Trials Michal Bar-Natan, MD is currently running
ABL001 Combo Therapy
for Leukemia
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL). It is expected that 25-40 people will take part in this research study. * ABL001 * Dasatinib (Sprycel®) * Prednisone * Blinatumomab
Recruiting1 award Phase 1
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
More about Michal Bar-Natan, MD
Clinical Trial Related5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Michal Bar-Natan, MD has experience with
- Cytarabine
- Dasatinib
- Prednisone
- ABL001
- Mutant CALR-peptide Based Vaccine
- Inotuzumab Ozogamicin
Breakdown of trials Michal Bar-Natan, MD has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michal Bar-Natan, MD specialize in?
Michal Bar-Natan, MD focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved BCR-ABL1 positive patients, or patients who are CD19 positive.
Is Michal Bar-Natan, MD currently recruiting for clinical trials?
Yes, Michal Bar-Natan, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Michal Bar-Natan, MD has studied deeply?
Yes, Michal Bar-Natan, MD has studied treatments such as Cytarabine, Dasatinib, Prednisone.
What is the best way to schedule an appointment with Michal Bar-Natan, MD?
Apply for one of the trials that Michal Bar-Natan, MD is conducting.
What is the office address of Michal Bar-Natan, MD?
The office of Michal Bar-Natan, MD is located at: Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Icahn School of Medicine at Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.